EBOS Group Outlines Medium-Term Growth Strategy and Capex Pivot

EBOS Group Limited (EBO.AX) has detailed its strategic roadmap during a recent Investor Day in Sydney, focusing on a transition toward higher-return business segments and disciplined capital allocation. The healthcare and pharmaceutical distributor is pivoting its portfolio to prioritize medical technology and animal care, following a five-year period in which the company redeployed approximately $2 billion into these higher-growth areas. Management expects capital expenditure to reach its peak in fiscal 2026. A subsequent decline in capex starting in fiscal 2027 is projected to support earnings per share (EPS) growth beginning in fiscal 2028, as the company moves from an investment phase to a period of realized returns. Over the medium term, the group is targeting organic underlying EBITDA growth in the mid-single-digit range. This growth is expected to be driven by the strategic shift toward higher-margin segments and operational efficiencies across its distribution network. Additionally, the company reaffirmed its commitment to shareholder returns, maintaining a dividend payout ratio of 60% to 80% of underlying net profit after tax (NPAT). This policy underscores management's confidence in the company's cash flow generation capabilities as capital spending eases.